Literature DB >> 33176618

Lack of evidence for the use of ustekinumab for acute severe ulcerative colitis.

Jonathan P Segal1, Mohammed Nabil Quraishi2,3.   

Abstract

Entities:  

Year:  2021        PMID： 33176618      PMCID： PMC8259243          DOI： 10.1177/2050640620972959

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  2 in total

1.  Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

Authors:  Bruce E Sands; William J Sandborn; Remo Panaccione; Christopher D O'Brien; Hongyan Zhang; Jewel Johanns; Omoniyi J Adedokun; Katherine Li; Laurent Peyrin-Biroulet; Gert Van Assche; Silvio Danese; Stephan Targan; Maria T Abreu; Tadakazu Hisamatsu; Philippe Szapary; Colleen Marano
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

2.  Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.

Authors:  Thomas Ochsenkühn; Cornelia Tillack; Daniel Szokodi; Shorena Janelidze; Fabian Schnitzler
Journal:  United European Gastroenterol J       Date:  2019-12-12       Impact factor: 4.623
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.